These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38548272)

  • 1. Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Wielpütz MO; Mall MA
    Eur Respir J; 2024 Mar; 63(3):. PubMed ID: 38548272
    [No Abstract]   [Full Text] [Related]  

  • 2. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Dooney M; Saba T
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
    [No Abstract]   [Full Text] [Related]  

  • 3. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?
    Merrill TB; Tyes J; Woodard TD
    Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Burgel PR
    Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
    [No Abstract]   [Full Text] [Related]  

  • 5. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
    Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
    Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
    McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
    J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor.
    Meltzer LJ; Gross JE
    J Cyst Fibros; 2024 Jan; 23(1):132-136. PubMed ID: 37210228
    [No Abstract]   [Full Text] [Related]  

  • 8. How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
    Ben-Meir E; Grasemann H
    Am J Respir Crit Care Med; 2022 Aug; 206(3):240-242. PubMed ID: 35579627
    [No Abstract]   [Full Text] [Related]  

  • 9. Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor.
    Mingora CM; Caverly LJ
    J Cyst Fibros; 2024 Jan; 23(1):3-4. PubMed ID: 38307802
    [No Abstract]   [Full Text] [Related]  

  • 10. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 11. Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis.
    Martin I; McDonald N; Wilson D; Ratjen F; Grasemann H
    J Cyst Fibros; 2024 Jan; 23(1):109-111. PubMed ID: 37867075
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
    Nichols D; Gifford A; Russell R; Odem-Davis K; Young J; Amaro-Galvez R; Billings J; Mukadam Z; Mayer-Hamblett N
    Ann Am Thorac Soc; 2024 Feb; 21(2):360-362. PubMed ID: 38019099
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.
    Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL
    Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224
    [No Abstract]   [Full Text] [Related]  

  • 14. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
    Nathan N; Thouvenin G; Dubern B; Corvol H
    Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
    O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF
    Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033
    [No Abstract]   [Full Text] [Related]  

  • 16. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
    Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
    Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
    Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
    J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
    [No Abstract]   [Full Text] [Related]  

  • 19. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.
    Bacon DR; Stapleton A; Goralski JL; Ebert CS; Thorp BD; Nouraie M; Shaffer AD; Senior BA; Lee SE; Zemke AC; Kimple AJ
    Int Forum Allergy Rhinol; 2022 Feb; 12(2):223-226. PubMed ID: 34709729
    [No Abstract]   [Full Text] [Related]  

  • 20. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.